A liver cancer diagnosis is a terrible one, because you can’t use chemo to treat it. There is not a lot of treatments to help you. My dad died from liver cancer a year ago. I am crossing my fingers that a new selective chemo drug may be on the way.
It is a feeling that many who receive a cancer diagnosis can identify with: heartbreak and fear, followed by hopes that chemotherapy will save the day. Unfortunately, for many patients, chemo’s painful side effects cause them to stop treatment prematurely.
Related: Israelis look to the Rambam to heal cancer
Now, a research team headed by Professor Alexander Binshtok, head of the Pain Plasticity Research Group at the Hebrew University of Jerusalem’s Faculty of Medicine and Edmond & Lily Safra Center for Brain Sciences, has developed a method that delivers chemotherapy drugs directly to malignant cells and bypasses healthy ones. This discovery could allow doctors to reduce chemo doses for patients, thereby reducing the unpleasant side-effects associated with the treatment, and improve treatment compliance and overall prognosis.
“Most anti-cancer treatments are not sufficiently specific, meaning they attack healthy cells together with the malignant ones they’re trying to get rid of,” explained Binshtok. “This leads to the many serious side-effects associated with chemotherapy. Eliminating cancerous cells while leaving healthy ones alone is an important step towards reduce patients’ suffering.”
The new findings were published in a recent issue of Frontiers in Pharmacology. The study focuses on the selective expression of the TRPV2 protein by cancer cells. When activated, TRPV2 protein opens a canal inside cell membranes.
Binshtok and his team studied liver cancer cells and were able to successfully insert a low dose of doxorubicin, a chemotherapeutic agent, through the canal and directly into cancer cells. Not only did the new method target cancer cells without harming healthy ones. In the future, the precision of this delivery method may allow doctors to prescribe lower chemo doses and to relieve patients from some of the harsher effects of chemo.
“It’s too early to make concrete predictions but we are hopeful this discovery will lead the way towards a new, more targeted delivery method for chemotherapy treatment, one that will drastically reduce patients’ pain,” Binshtok concluded.
The treatment is much needed because current treatments mostly only prolong life by a few months after the tumors have grown to a certain size and can no longer be ablated. This new research might help improve the outcomes of chemotherapy given directly into the liver (chemoembolization) to reduce tumors to a size that may make surgery possible.
Author: Karin Kloosterman
Karin Kloosterman is an award-winning journalist, innovation strategist, and founder of Green Prophet, one of the Middle East’s pioneering sustainability platforms. She has ranked in the Top 10 of Verizon innovation competitions, participated in NASA-linked challenges, and spoken worldwide on climate, food security, and future resilience. With an IoT technology patent, features in Canada’s National Post, and leadership inside teams building next-generation agricultural and planetary systems — including Mars-farming concepts — Karin operates at the intersection of storytelling, science, and systems change. She doesn’t report on the future – she helps design it. Reach out directly to [email protected]
